CELLS

Tumour-host interactions in Drosophila: mechanisms in the tumour micro- and macroenvironment.

Traditionally, cancer has been viewed largely as a disease of the cell, with extensive research centred on how mutations in driver genes trigger cellular transformation. Beyond cell-intrinsic changes, cancer unfolds as a systemic disease driven by an intricate dialogue between...

🗓️ 2026-01-17
📰 Publication: Molecular Oncology
Read MoreTumour-host interactions in Drosophila: mechanisms in the tumour micro- and macroenvironment.

Tumor intrinsic properties dictate Fc receptor expression and cancer cachexia associated increase in checkpoint inhibitor clearance.

PURPOSE

Patients with cancer cachexia display a general resistance to immune checkpoint inhibitor (ICI) therapy, and baseline ICI catabolic clearance is a predictive indicator for overall survival, independent of dose and drug exposure. Fc-gamma (FcγRs) and neonatal Fc receptors (FcRn) play...

🗓️ 2026-01-02
📰 Publication: Frontiers In Immunology
Read MoreTumor intrinsic properties dictate Fc receptor expression and cancer cachexia associated increase in checkpoint inhibitor clearance.

Secreted protein acidic and rich in cysteine-guided biomimetic delivery of nano-antioxidants reverses muscle atrophy in a mouse model of sarcopenia.

Sarcopenia is currently classified as an unmet medical need with an increasing incidence because of population aging. Excessive reactive oxygen species (ROS) production plays a critical role in the pathogenesis of muscle atrophy, a key feature of sarcopenia, whereas edaravone...

🗓️ 2025-12-25
📰 Publication: Journal Of Controlled Release
Read MoreSecreted protein acidic and rich in cysteine-guided biomimetic delivery of nano-antioxidants reverses muscle atrophy in a mouse model of sarcopenia.

CXCL5 neutralization mitigates cancer cachexia by disrupting CAF-cancer cell crosstalk.

BACKGROUND

Advanced metastasis produces cachexia, a complex skeletal muscle wasting syndrome that accounts for one-third of patient deaths. There is currently no approved drug therapy for cancer cachexia. Cancer-associated fibroblasts (CAF) within tumors have been hypothesized to contribute to cachexia, but...

🗓️ 2025-12-15
📰 Publication: Journal Of Biomedical Science
Read MoreCXCL5 neutralization mitigates cancer cachexia by disrupting CAF-cancer cell crosstalk.

Decorin Deficiency Promotes D-Galactose-Induced Skeletal Muscle Atrophy and Fibrosis by Regulating ITGB1/Akt/mTOR Signalling Pathway.

BACKGROUND

Primary sarcopenia is an age-associated disorder with progressive and generalised loss of skeletal muscle strength and mass. Skeletal muscle fibrosis is one of the significant pathological manifestations of age-associated sarcopenia. Decorin, a small dermatan-sulfate proteoglycan, participates in extracellular matrix assembly....

🗓️ 2025-12-06
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreDecorin Deficiency Promotes D-Galactose-Induced Skeletal Muscle Atrophy and Fibrosis by Regulating ITGB1/Akt/mTOR Signalling Pathway.

C2C12-Derived ApoVs Promote Skeletal Muscle Development and Ameliorate Age-Related Muscle Loss Through Igf1r/PI3K/AKT/mTOR Pathway.

BACKGROUND

Apoptosis coincides with the differentiation of skeletal myoblasts, and numerous studies have shown that the apoptotic activity is required for myogenic differentiation. Although the role of apoptosis in skeletal muscle differentiation has been well documented, its mechanism is largely unknown.

METHODS

Apoptotic...

🗓️ 2025-12-05
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreC2C12-Derived ApoVs Promote Skeletal Muscle Development and Ameliorate Age-Related Muscle Loss Through Igf1r/PI3K/AKT/mTOR Pathway.

From Symptom to Outcome: Defining Clinically Meaningful Patient-Reported Appetite Loss in Non-Small-Cell Lung Cancer.

BACKGROUND

Appetite loss is a common and distressing symptom in non-small-cell lung cancer (NSCLC), driven by both treatment side effects and disease progression. It often leads to unintended weight loss and cancer cachexia, significantly impairing patients' quality of life and survival....

🗓️ 2025-12-04
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreFrom Symptom to Outcome: Defining Clinically Meaningful Patient-Reported Appetite Loss in Non-Small-Cell Lung Cancer.

Umbilical cord mesenchymal stromal cells in sarcopenia: benefits and strategies for enhancing efficacy.

Sarcopenia is a progressive age-related condition characterized by the decline of skeletal muscle mass and function. Its development involves multiple cellular and molecular mechanisms, including chronic inflammation, apoptosis, mitochondrial dysfunction, and impaired muscle regeneration. Human umbilical cord mesenchymal stromal cells...

🗓️ 2025-12-03
Read MoreUmbilical cord mesenchymal stromal cells in sarcopenia: benefits and strategies for enhancing efficacy.

Evaluation of Weight Gain and Overall Survival of Men Versus Women With Advanced Non-Small Cell Lung Cancer.

BACKGROUND

Weight stabilization or gain during cancer treatment is associated with increased survival. Analyses of weight gain by sex during cancer treatment and the effects of weight on survival have not been fully studied. This post hoc analysis retrospectively examined the...

🗓️ 2025-12-03
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreEvaluation of Weight Gain and Overall Survival of Men Versus Women With Advanced Non-Small Cell Lung Cancer.

Alternative Splicing of SORBS1 Affects Neuromuscular Junction Integrity in Myotonic Dystrophy Type 1.

BACKGROUND

Myotonic dystrophy type 1 (DM1) is a multisystemic neuromuscular disorder characterized by CTG repeat expansion in the 3' untranslated region of the dystrophia myotonica protein kinase coding gene. The presence of expanded CTG repeats in DMPK mRNAs leads to the...

🗓️ 2025-11-18
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreAlternative Splicing of SORBS1 Affects Neuromuscular Junction Integrity in Myotonic Dystrophy Type 1.

Pathways Contributing to Chemotherapy-Induced Myotoxicity Are Attenuated by EPA + DHA in a Clinically Relevant Model of Colorectal Cancer.

BACKGROUND

Skeletal muscle loss is a well-recognized consequence of cancer, and chemotherapy exacerbates myotoxicity through multiple mechanisms. Retaining muscle mass improves tumour response to therapies and tolerance to chemotherapy; hence, interventions to mitigate myotoxicity warrant investigations. This study aimed to investigate...

🗓️ 2025-11-17
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MorePathways Contributing to Chemotherapy-Induced Myotoxicity Are Attenuated by EPA + DHA in a Clinically Relevant Model of Colorectal Cancer.

Skeletal muscle-derived IL-33 mediates muscle-to-bone crosstalk and regulates bone metabolism via CD8 + T cell-secreted CCL5.

BACKGROUND

Skeletal muscle-to-bone crosstalk may play critical roles in the association between muscle atrophy and bone loss. Here, we report a myokine, IL-33, which may mediate muscle-to-bone crosstalk.

METHODS

A cohort study was conducted to elucidate the associations among circulating IL-33, osteoporosis, and...

🗓️ 2025-11-15
📰 Publication: Ebiomedicine
Read MoreSkeletal muscle-derived IL-33 mediates muscle-to-bone crosstalk and regulates bone metabolism via CD8 + T cell-secreted CCL5.

STX4 Is Indispensable for Mitochondrial Homeostasis in Skeletal Muscle.

BACKGROUND

Mitochondrial homeostasis is vital for optimal skeletal muscle integrity. Mitochondrial quality control (MQC) mechanisms that are essential for maintaining proper functions of mitochondria include mitochondrial biogenesis, dynamics and mitophagy. Previously, Syntaxin 4 (STX4), traditionally considered a cell surface protein known...

🗓️ 2025-11-11
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreSTX4 Is Indispensable for Mitochondrial Homeostasis in Skeletal Muscle.

Muscle Structure and Function Recovery: Adalimumab-Calcium Channel Synergy in Post-Ischemic Stroke Sarcopenia.

BACKGROUND

Adalimumab, a TNF-α inhibitor, is widely used clinically. Recent studies suggest Adalimumab can improve muscle damage after ischemic stroke (IS), but its protective mechanisms remain unclear. This study investigates the effect of adalimumab on muscle structure post-IS and the role...

🗓️ 2025-11-10
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreMuscle Structure and Function Recovery: Adalimumab-Calcium Channel Synergy in Post-Ischemic Stroke Sarcopenia.

Targeting Progesterone Receptor Membrane Component 1 to Improve Muscle Development and Glucose Homeostasis.

BACKGROUND

Type 2 diabetes mellitus (T2D) arises from the interplay between peripheral insulin resistance and pancreatic β-cell dysfunction, ultimately leading to impaired glucose utilization and chronic hyperglycemia. Despite therapeutic advances, the multifactorial nature of T2D continues to demand the development of...

🗓️ 2025-11-10
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreTargeting Progesterone Receptor Membrane Component 1 to Improve Muscle Development and Glucose Homeostasis.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!